Senti Bio to Discuss SENTI-202 Clinical Data in Conference Call
Senti Biosciences, Inc. (Nasdaq: SNTI) is set to host a conference call focused on the latest clinical results from SENTI-202, a groundbreaking CAR-NK cell therapy, at the upcoming ASH Annual Meeting. This event is scheduled for December 9 at 8:00 AM ET, providing a unique opportunity for stakeholders to gain insights into the innovative research being conducted by the company.
Details of the Event
Joining the conference call will be prominent company figures, including Timothy Lu, MD, PhD, the CEO and Co-Founder of Senti Bio, alongside Kanya Rajangam, MD, PhD, the President and Chief Medical Officer. They will be joined by Dr. Nosha Farhadfar, a Hematologist and Bone Marrow Transplant Physician from the Sarah Cannon Transplant & Cellular Therapy Program. Participants eager to listen in can dial (877) 524-8416 for domestic access or +1 (412) 902-1028 for international callers.
Accessing the Webcast
The call will be made available via a webcast on the company’s official website, ensuring that those unable to attend the live session can later access the discussion. The webcast will be archived for 90 days following the event, allowing for continued exploration of the insights shared during the call.
Diving into SENTI-202
SENTI-202 stands out as the inaugural Logic Gated off-the-shelf CAR-NK cell therapy product, adeptly engineered to selectively eliminate CD33 and/or FLT3 expressing hematologic malignancies such as AML and myelodysplastic syndrome (MDS), without harming healthy bone marrow cells. This cutting-edge therapy comprises three key components:
Components of SENTI-202
The first element, the OR GATE, is an activating CAR engineered to identify and destroy cells expressing CD33 and/or FLT3. This allows SENTI-202 to effectively target both leukemic blasts and stem cells, which are notoriously challenging to eradicate. Secondly, the NOT GATE serves as an inhibitory CAR, recognizing EMCN, which is selectively expressed on healthy cells. This vital function provides a protective mechanism to healthy hematopoietic stem cells even if they express the target antigens. The third innovation is a calibrated-release IL-15 that enhances the persistence, expansion, and activity of CAR-NK cells and surrounding immune cells.
Clinical Trials and Progress
Senti Bio is in the process of enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies for a Phase 1 clinical trial of SENTI-202. This therapy is poised to potentially be the first-in-class allogeneic treatment option for patients suffering from AML and MDS.
About Senti Bio
Senti Bio is at the forefront of developing next-generation cell and gene therapies aimed at addressing critical needs for patients afflicted by incurable diseases. The company's innovative approach leverages synthetic biology to create Gene Circuits, which enhance precision and control in targeting tumors. This unique methodology ensures that cancer cells are effectively targeted while preserving healthy cells, thereby refining the therapeutic experience for patients.
Investment and Future Development
As Senti Bio continues to explore various pathways to enhance their treatment offerings, they maintain a strong focus on progressing their proprietary Gene Circuit platform. This strategic initiative supports advancements not only in oncology but also across diverse therapeutic areas. The ongoing success of Senti Bio's clinical trials promises to enhance their impact in the biotechnology industry.
Frequently Asked Questions
What is the purpose of the conference call hosted by Senti Bio?
The conference call aims to provide insights into the clinical results of SENTI-202 being presented at the ASH Annual Meeting.
Who are the key speakers during the Senti Bio conference call?
Timothy Lu, MD, PhD, and Kanya Rajangam, MD, PhD, will be leading the discussion, joined by Dr. Nosha Farhadfar.
How can investors access the conference call?
Investors can dial in at (877) 524-8416 domestically or +1 (412) 902-1028 internationally to participate in the call.
What is SENTI-202 targeting?
SENTI-202 targets CD33 and/or FLT3 expressing hematologic malignancies while preserving healthy cells.
How does Senti Bio prioritize therapy development?
Senti Bio is committed to developing innovative therapies through its Gene Circuit platform, aiming for enhanced precision in treating patients with incurable diseases.
